Recent submissions

Comment · 5 years ago
Comment · 5 years ago
Metallic taste - adjuvant? (just a guess...)
Comment · 5 years ago
It is not because unvaccinated would pose a threat to others but because they are at risk of catching the disease from a vaccinated, infected but asymptomatic guest

Haven't read your link yet but I'd expect a double vaccinated 65 year old is still waaaaay more vulnerable than an unvaccinated 18 year old.

Comment · 5 years ago
For the low risk groups it's a small absolute risk reduction of hospitalisation, and extremely small absolute risk reduction of death. But given that herd immunity is now impossible to achieve, the long term impact on the high risk groups will be limited.

I expect what could see is stubbornly elevated hospitalization and deaths in the high risk groups :( Bad for them but also bad because the way that politicians trying to drive health policy under mistaken assumptions will react.

Comment · 5 years ago
The study found that effectiveness dropped to 80% for patients over the age of 65, while for younger patients, the vaccines were 95% effective.

Let that sink in for a moment...

The best way to boost overall vaccine effectiveness is to extend it lower risk groups - healthy children and young people - regardless of whether they really need it or not.

Comment · 5 years ago
Comment · 5 years ago
Comment · 5 years ago
The problem of Ivermectin trials based in Latin American countries is that community Ivermectin use is so widespread, it becomes a major confounder in trials because most of the 'placebo' group could be using it.

'Latin America’s embrace of an unproven COVID treatment is hindering drug trials'

https://www.nature.com/articles/d41586-020-02958-2

Hopefully it would be noted in the limitations section of the trial paper, but the writers of media articles are often polarized or biased and just cherry pick.

ETA, personally I would prefer small well designed trials from researchers with historical expertise who provide plenty of accompanying information and are willing to discuss the results, eg Chaccour et al:

'The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial'

https://www.thelancet.com/journals/eclinm/article/PIIS2589-5...

https://www.youtube.com/watch?v=yIUO08W94eY https://www.youtube.com/watch?v=JuzHG0rpOrc

Comment · 5 years ago
Comment · 5 years ago
Please, if there is any misinformation in the article, tell us where it is.

IMO a number of high profile politicians and corporate media are also guilty of misinformation.

Eg 'pandemic of the unvaccinated'. This seems to equate no immunity with naturally acquired immunity, and must surely be misinformation, but much of the media is blind to it.

Comment · 5 years ago
See how this guy misrepresents the study on TWiV episode 783.

https://youtu.be/73KWHPsw-ag?t=525

He states that '4% seropositive having symptoms after 12 weeks', but omits to mention that 2% of seronegative have symptoms after 12 weeks too...

Also he doesn't mention the 9%/10% rate split at 4 weeks, or the symptoms:

Tiredness, Headache, Congested or runny nose, Stomachach, Sleep disturbances, Cough

So he's making the case for child vaccination on the basis of 2 extra seropositive children having one or more of the above symptoms.

And, BTW, the study authors themselves note the limitations as follows:

'Limitations include the relatively small number of seropositive children, possible misclassification of some false seropositive children, potential recall bias, parental report of child’s symptoms, and lack of information on symptom severity.'

The study authors concluded that:

'Seropositive children, all with a history of pauci-symptomatic SARS-CoV-2 infection, did not report long COVID more frequently than seronegative children. This study suggests a very low prevalence of long COVID in a randomly selected population-based cohort of children followed over 6 months after serological testing.'

Comment · 5 years ago
Comment · 5 years ago
Headline is misleading, it would be better to say 'why Delta is so much more transmissable'

According to the UK govt's own figures, the 28 day case fatility rate is 2.0% for the Alpha variant, and 0.3% for the Delta variant.

See page 8:

https://assets.publishing.service.gov.uk/government/uploads/...

OK it may be that hospital treatment and vaccination (of the vulnerable) have greatly improved the CFR, but as of now mortality risk of the Delta variant is rather more modest compared to some earlier variants.

Comment · 5 years ago
>Even worse I am having a tough time putting my finger on what the shortcoming of these people is.

Polarization is the mRNA of disinformation.

Live from the official Hacker News API

A modern reader for Hacker News · SvelteKit + Skeleton